Consensus Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
1.32 ^USD	+4.76%		+1.54%	+12.82%

Apr. 16	Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors	CI
Mar. 18	Clearside Biomedical Names Victor Chong Chief Medical Officer	MT

Evolution of the average Target Price on Clearside Biomedical, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a.wK0IZ4WXPid1J_X-8tr5wcQ5MqadDVulc6XAtMuLyg4.7f1qDMPTcXYZbcepnOjAlrVhA_HUIDicH8q2wqC7-maLmVoi3ch8Hw14xQ~c138b7df969bd9016f344e3bb3ccd0e3

Analyst Recommendations on Clearside Biomedical, Inc.

Wedbush Trims Clearside Biomedical's PT to $4 From $5 After Increased Share Count, Model Adjustments; Maintains Outperform Rating	Mar. 13	MT
JonesTrading Intiates Coverage on Clearside Biomedical With Buy Rating, $6 Price Target	23-06-14	MT
Needham Adjusts Price Target on Clearside Biomedical to $4 From $5, Maintains Buy Rating	23-03-10	MT
JMP Securities Adjusts Clearside Biomedical Price Target to $6 From $7, Maintains Market Outperform Rating	23-03-10	MT
Wedbush Lifts Clearside Biomedical's Price Target to $5 From $4 After Model Adjustments, Keeps Outperform Rating	23-03-10	MT
Wedbush Adjusts Clearside Biomedical's Price Target to $4 From $6, Keeps Outperform Rating	23-02-03	MT
Wedbush Adjusts Clearside Biomedical Price Target to $4 From $6, Maintains Outperform Rating	23-02-02	MT
Needham Upgrades Clearside Biomedical to Buy Rating From Hold, Price Target is $5	22-11-10	MT
Stifel Upgrades Clearside Biomedical to Buy From Hold, Price Target is $8	22-11-10	MT
Wedbush Lowers Clearside Biomedical's Price Target to $6 From $9, Keeps Outperform Rating	22-11-10	MT
HC Wainwright Adjusts Clearside Biomedical's Price Target to $5 from $10, Keeps Buy Rating	22-08-10	MT
Wedbush Removes Outperform-Rated Clearside Biomedical From Best Ideas List; Price Target is $9	22-01-24	MT
Wedbush Adds Outperform-Rated Clearside Biomedical to Best Ideas List, Citing 'Potentially Transformative Dual Approach' for wAMD Treatment, Adjusts PT to $9 From $19 on Peak Sale Estimates	21-12-15	MT
Roth Capital Adjusts Clearside Biomedical's Price Target to $17 From $15, Reiterates Buy Rating	21-10-26	MT
CLEARSIDE BIOMEDICAL : Wedbush Lifts Price Target for Clearside Biomedical to $19 From $18, Maintains Outperform Rating	21-10-25	MT
CLEARSIDE BIOMEDICAL : HC Wainwright Starts Clearside Biomedical at Buy With $10 Price Target	21-07-29	MT
CLEARSIDE BIOMEDICAL : Roth Capital Adjusts Price Target on Clearside Biomedical to $15 From $9, Maintains Buy Rating	21-06-18	MT
CLEARSIDE BIOMEDICAL : Wedbush Adjusts PT on Clearside Biomedical to $18 From $6 on CLS-AX Potential in Treating Wet Age-Related Macular Degeneration; Outperform Rating Kept	21-06-17	MT
CLEARSIDE BIOMEDICAL : Stifel Adjusts Clearside Biomedical's Price Target to $5 From $3.50, Maintains Hold Rating	21-06-15	MT
CLEARSIDE BIOMEDICAL : JMP Securities Adjusts Clearside Biomedical PT to $9 From $8, Maintains Market Outperform Rating	21-06-15	MT
CLEARSIDE BIOMEDICAL : Roth Capital Adjusts Clearside Biomedical PT to $9 From $8, Maintains Buy Rating	21-05-18	MT
CLEARSIDE BIOMEDICAL : Wedbush Adjusts Price Target on Clearside Biomedical to $6 From $5, Keeps Outperform Rating	21-02-22	MT